We also found decreased copy numbers of known tumor suppressors, including map2k, ppp2r, and pten. Given the strong similarities between our mouse model and aggressive human breast cancers, the TBP model provides an invaluable preclinical platform to identify and assess potential therapeutics for aggressive and chemoresistant breast cancer subtypes [42], [43]. Here, PTEN is linked to neoplasm.